Announcements
Excerpt from the Press Release: HAMILTON, ON and BOSTON, Nov. 16, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials. Under…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that researchers will present data from an ongoing phase 2 trial study of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM), at the Society for Neuro-Oncology Annual Meeting…
Read More
Casgevy the 1st medicine licensed using the gene editing tool CRISPR Excerpt from the Press Release: Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the disease in the U.K. In a statement on Thursday, the Medicines…
Read More
Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S. Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov. 7, 2023– Veracyte, Inc. (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing…
Read More
– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Artiva Biotherapeutics, Inc., a clinical stage company with the mission to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced it has been awarded Immunology Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the…
Read More
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines. The publication in the journal mBio is titled “mRNAs encoding…
Read MorePoster also details clinical readiness for CLDI-201 and plans to initiate Phase 1 study in 2024 Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of new preclinical data from the company’s CLD-201 (SuperNova)…
Read More
Phase 1 trial underway for Terns’ first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24 Oral GLP-1R agonist offers potential for weight loss and improved convenience compared to currently marketed injectables Excerpt from the Press Release: FOSTER CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc.…
Read More
Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting KB-0742 demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors …
Read More